Diagnostic and prognostic utility of bone morphogenetic protein 10 in acute dyspnea: a cohort study

• Published in: Clinical research in cardiology 2024-12
• Main Authors: Simonavicius, Justas, Wussler, Desiree, Belkin, Maria, Luening, Karoline, Lopez-Ayala, Pedro, Strebel, Ivo, Shrestha, Samyut, Nowak, Albina, Michou, Eleni, Papachristou, Androniki, Popescu, Codruta, Kozhuharov, Nikola, Sabti, Zaid, Reiffer, Zora, Hennings, Elisa, Zimmermann, Tobias, Diebold, Matthias, Breidthardt, Tobias, Mueller, Christian
• Format: Article
• Language: English
• ISSN: 1861-0692

The possible clinical utility of Bone Morphogenetic Protein 10 (BMP10), a novel atrial-specific biomarker, is incompletely understood. We aimed to test the hypothesis that BMP10 has high diagnostic and prognostic accuracy in patients presenting with acute dyspnea. In a multicenter diagnostic study, BMP10, high-sensitivity cardiac troponin T (hs-cTnT), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations were determined in patients presenting with acute dyspnea to the emergency department. The final diagnosis was centrally adjudicated by two independent cardiologists blinded to BMP10. Diagnostic accuracy for acute heart failure (AHF) was quantified using the area under the receiver operating characteristic curve (AUC). 720-day all-cause mortality and the composite of all-cause mortality or AHF rehospitalization were prognostic endpoints. Among 933 consecutive patients, 54% were adjudicated to have AHF. Patients with AHF had higher BMP10 concentrations (median 3.34 [IQR 2.55-4.35] ng/mL) compared to patients with other causes of acute dyspnea (2.04 [1.74-2.45] ng/mL, p